Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Author Interviews
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research

User menu

  • My alerts

Search

  • Advanced search
Life Science Alliance
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research
  • My alerts
Life Science Alliance

Advanced Search

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Author Interviews
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Follow lsa Template on Twitter
Research Article
Source Data
Transparent Process
Open Access

Role of opioid signaling in kidney damage during the development of salt-induced hypertension

Daria Golosova, View ORCID ProfileOleg Palygin, Ruslan Bohovyk, Christine A Klemens, Vladislav Levchenko, Denisha R Spires, View ORCID ProfileElena Isaeva, Ashraf El-Meanawy, View ORCID ProfileAlexander Staruschenko  Correspondence email
Daria Golosova
1Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oleg Palygin
1Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA
2Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Oleg Palygin
Ruslan Bohovyk
1Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine A Klemens
1Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladislav Levchenko
1Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denisha R Spires
1Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Isaeva
1Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elena Isaeva
Ashraf El-Meanawy
2Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA
3Division of Nephrology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Staruschenko
1Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA
2Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA
4Clement J. Zablocki VA Medical Center, Milwaukee, WI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexander Staruschenko
  • For correspondence: staruschenko@mcw.edu
Published 12 October 2020. DOI: 10.26508/lsa.202000853
  • Article
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Supplementary Materials
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1. [Ca2+]i flux in response to application of opioid receptor (OR) agonists in podocytes from freshly isolated rat glomeruli.

    (A) Representative image of a glomerulus loaded with ratiometric calcium dyes (Fluo-4/Fura 2TH; merged) before and after the application of specific κ-OR agonist (100 μM, BRL 52537). Scale bar is 50 μm. (B) Response of podocytes to different OR agonists (κ-OR – 100 μM BRL 52537, μ-OR – 100 μM DAMGO, or δ-OR – 50 μM DPDPE). (C) Summary for the peak fluorescence intensity following an application of the OR agonists shown at B (n ≥ 30 podocytes; one-way ANOVA, P < 0.001, Tukey’s post hoc P < 0.05).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2. κ-opioid receptor (OR) activation causes [Ca2+]i mobilization via TRPC6 channels in human immortalized podocytes.

    (A) Representative example of specific κ-OR agonist (100 μM, BRL 52537) application in the presence or absence of extracellular calcium (Fluo4 AM fluorescence). Scale bar is 50 μm. Images shown in Fig 2A are taken at 1, 1.5, and 6 min from the start of experiments either in 0 or 2 mM [Ca2+]ex (bottom and top images, respectively). The source data videos are available; 1 min of experiments equals to ∼2 s in the videos. (B) Mean [Ca2+]i transient in human podocytes after κ-OR stimulation in 2 or 0 mM calcium-containing bath solution (top and bottom traces, respectively). (C) Dose–response plot for peak [Ca2+]i increase induced by BRL 52537 (2 mM [Ca2+ ]ex) in human podocyte culture (a number of podocytes analyzed per point on the graph are shown). (D) Representative traces show dose-dependent changes in [Ca2+]i after applications of BRL 52537. (B, E) Peak amplitude of the [Ca2+]i after κ-OR agonist stimulation in experiments shown in (B), or during a preincubation of human podocytes with κ-OR antagonist (norBNI) or TRPC6 inhibitor (100 nM, SAR7334) in 2 mM [Ca2+]ex (n ≥ 38 cells; one-way ANOVA, P < 0.001, Tukey’s post hoc P < 0.05, all pairwise k = 6).

    Source data are available online for this figure.

    Source Data for Figure 2[LSA-2020-00853_SdataF2.1.avi][LSA-2020-00853_SdataF2.2.avi]

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3. Assessment of cytosolic calcium response to κ-opioid receptor (OR)/TRPC6 pathway activation in podocytes of the freshly isolated human glomerulus.

    (A) Peak amplitude of the [Ca2+]i transient mediated by κ-OR agonist stimulation shown in (B) (n ≥ 33 cells; ANOVA, P < 0.001). (B) [Ca2+]i response in podocytes from freshly isolated human glomeruli exposed to κ-OR agonist (100 μM, BRL 52537) under control or TRPC6 blockade (50 μM, SAR7334 preincubation) conditions.

  • Figure S1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S1. Assessment of κ-opioid receptor (OR) expression in podocytes of the freshly isolated human glomerulus.

    (A) Immunolabeling of isolated human glomerulus indicated a co-localization of podocin (green; FITC) and κ-OR (red; TRITC). Scale bars are 20 μm. (B) Representative immunohistochemical staining of κ-OR protein in human kidney at 20× and 40× magnification. Podocytes are marked with arrows. Scale bars are 50 μm.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4. κ-opioid receptor (OR) agonist induces podocyte cell shape changes via the actin cytoskeleton remodeling.

    (A) An application of κ-OR agonist to human-cultured podocytes promotes significant shrinkage in the cell surface area (top panel, scale bar is 50 μm). Changes in the mean cell surface area were obtained by comparisons between BRL-treated and control cells (number of cells is indicated in the brackets, ANOVA, P < 0.001; panel below). (B) Following BRL-induced podocyte shrinkage, the actin cytoskeleton pattern shows reinforcement and formation of the actin stress fibers. The reorganization of the F-actin cytoskeleton is indicated by the changes in the rhodamine phalloidin staining pattern through the blue line. Scale bar is 50 μm. (C) Surface topography 3D images obtained by scanning ion-conductance microscopy shows lamellipodia dynamics in human podocytes treated with κ-ORs agonist (changes in z-axis indicated by pseudocolor). (D) Summary of scanning ion-conductance microscope topography indicates normal lamellipodial protrusion under control conditions followed by a strong retraction pattern mediated by κ-OR stimulation (n ≥ 3 cells; ANOVA, P < 0.002, Tukey’s post hoc P < 0.05).

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5. Chronic treatment with κ-opioid receptor (OR) agonist aggravates salt-induced hypertension and podocyte damage in Dahl salt-sensitive (SS) rats.

    (A) Schematic representation of the experimental protocol. (B) The development of mean arterial pressure in SS rats after changing the diet from a normal salt (NS, 0.4%; day 0) to a HS (8% NaCl) and chronic treatment with κ-OR agonist or vehicle (n ≥ 5 rat per group; ANOVA, P < 0.05). (C) Urinary albumin (Alb/Cre, 24 h collection) changes for the experiments shown in (B). (D) Basal calcium levels in podocytes of freshly isolated glomeruli from hypertensive SS rats chronically exposed to κ-OR agonist or vehicle (n ≥ 13 cells; ANOVA, P < 0.003). (E) Western blot analysis of nephrin in the urine samples (24-h collection) from hypertensive (2 wk on HS) and BRL-treated rats (n = 5 rats per group; ANOVA, P < 0.005).

  • Figure S2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S2. Qualitative and statistical comparisons of glomerular injury in hypertensive rats chronically treated with κ-OR agonist.

    (A) Representative section of Masson’s trichrome–stained kidney from hypertensive rats treated with vehicle or BRL. Scale bar is 150 μm. (B) Glomerular injury score (0–4; 0 is no damage) assessed by semi-quantitative morphometric analysis. Note the number of glomeruli count for each score on the y-axes. (C) Cumulative probability distributions of the obtained glomerular scores. The plot indicates the probability of a glomerulus having a score within the selected range. A trend towards increased glomerular damage is noted in the opioid-treated group.

  • Figure S3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S3. Expression of pro-caspase-3.

    Western blot analysis was conducted to determine pro-caspase-3 cleavage (n = 4 rats per group; ANOVA, P < 0.003, Tukey’s post hoc P < 0.05). Measurements were performed in the kidney cortex in normotensive (NS), hypertensive (14DHS), and hypertensive opioid-treated (14DHS+BRL) groups.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6. Increased TRPC6 expression leads to exacerbated podocyte apoptosis in response to κ-OR stimulation in hypertension.

    (A) Western blot analyses of the TRPC6 expression in the kidney cortex of normotensive (NS), hypertensive (14DHS), and hypertensive treated with BRL (14DHS+BRL) groups. (B) Summary graph of TRPC6 expression as shown in A (n = 4 rats per group, ANOVA, P < 0.03, Tukey’s post hoc P < 0.05). (C) Mean [Ca2+]i transient in podocytes of glomeruli freshly isolated from salt-sensitive rats fed normal salt (NS) or after 2 wk on HS (14DHS). Note the sustained [Ca2+]i response to acute stimulation of κ-ORs in hypertensive animals.

  • Figure S4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S4. Quantitative real-time PCR analysis of mRNA expression levels of TRPC6.

    Measurements were performed in the kidney cortex in normotensive (NS), hypertensive (14DHS), and hypertensive opioid-treated (14DHS+BRL) groups.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7. Schematic demonstrating the contribution of the κ-OR/TRPC6 pathway to the pathological elevation in [Ca2+]i, and consecutive podocyte foot processes retraction, apoptosis, and progression of renal damage in hypertension during opioid treatment.

Tables

  • Figures
  • Supplementary Materials
    • View popup
    Table 1.

    Blood electrolytes analysis of salt-sensitive rats during chronic experiment with or without treatment with the opioids within 14 d on HS.

    NSNS
    Potassium3.2 ± 0.13.4 ± 0.1
    Sodium143.8 ± 0.4141.4 ± 0.4
    Calcium1.35 ± 0.011.32 ± 0.01
    Chloride113 ± 4106 ± 2
    7DHS+Vehicle7DHS+BRL
    Potassium3.2 ± 0.13.1 ± 0.2
    Sodium146 ± 1150 ± 2*
    Calcium1.38 ± 0.011.30 ± 0.02
    Chloride104 ± 1110 ± 2*
    14DHS+Vehicle14DHS+BRL
    Potassium3.1 ± 0.13.0 ± 0.1
    Sodium143.3 ± 0.5146.7 ± 1.6
    Calcium1.36 ± 0.011.23 ± 0.04*
    Chloride101 ± 1106 ± 2
    • κ-OR agonist treated rats (1.5 mg/kg BRL 52537). NS (0.4% NaCl); 7DHS, 14DHS, 7 d and 14 d on HS (8% NaCl), respectively (n ≥ 5 rat per group; t test *P < 0.05, BRL- versus vehicle-treated rats on the same day of treatment).

    • View popup
    Table 2.

    Urine electrolytes/creatinine ratio in salt-sensitive rats during chronic opioid treatment within 14 d on HS.

    NSNS
    Potassium8.5 ± 215 ± 2
    Sodium33 ± 523 ± 2
    Calcium0.24 ± 0.040.26 ± 0.03
    Chloride44 ± 832 ± 3
    7DHS+Vehicle7DHS+BRL
    Potassium19 ± 316 ± 1
    Sodium437 ± 41327 ± 17*
    Calcium3.2 ± 0.52.9 ± 0.2
    Chloride402 ± 34310 ± 15*
    14DHS+Vehicle14DHS+BRL
    Potassium19 ± 115 ± 1*
    Sodium372 ± 30255 ± 9*
    Calcium2.9 ± 0.22.1 ± 0.1*
    Chloride323 ± 24241 ± 9*
    • κ-OR agonist treated rats (1.5 mg/kg BRL 52537). NS (0.4% NaCl); 7DHS, 14DHS – 7 d and 14 d on HS (8% NaCl), respectively (n ≥ 5 rat per group; t test *P < 0.05, BRL- versus vehicle-treated rats on the same day of treatment).

Supplementary Materials

  • Figures
  • Tables
  • Video 1

    Representative scanning ion-conductance microscope video demonstrates changes in lamellipodia dynamics in control and after the acute application of BRL in cultured human immortalized podocytes. Each scan is 4 min. Download video

PreviousNext
Back to top
Download PDF
Email Article

Thank you for your interest in spreading the word on Life Science Alliance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Role of opioid signaling in kidney damage during the development of salt-induced hypertension
(Your Name) has sent you a message from Life Science Alliance
(Your Name) thought you would like to see the Life Science Alliance web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Kappa opioid receptor in podocyte injury
Daria Golosova, Oleg Palygin, Ruslan Bohovyk, Christine A Klemens, Vladislav Levchenko, Denisha R Spires, Elena Isaeva, Ashraf El-Meanawy, Alexander Staruschenko
Life Science Alliance Oct 2020, 3 (12) e202000853; DOI: 10.26508/lsa.202000853

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Kappa opioid receptor in podocyte injury
Daria Golosova, Oleg Palygin, Ruslan Bohovyk, Christine A Klemens, Vladislav Levchenko, Denisha R Spires, Elena Isaeva, Ashraf El-Meanawy, Alexander Staruschenko
Life Science Alliance Oct 2020, 3 (12) e202000853; DOI: 10.26508/lsa.202000853
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
Issue Cover

In this Issue

Volume 3, No. 12
December 2020
  • Table of Contents
  • Cover (PDF)
  • About the Cover
  • Masthead (PDF)
Advertisement

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Acknowledgements
    • References
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF

Subjects

  • Medical Research
  • Physiology

Related Articles

  • No related articles found.

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Misidentification of m5C at GCU in ONT direct RNA sequencing
  • BRCA2 homolog of Naganishia yeast
  • PARP-1 fine-tunes gene expression in development
Show more Research Article

Similar Articles

EMBO Press LogoRockefeller University Press LogoCold Spring Harbor Logo

Content

  • Home
  • Newest Articles
  • Current Issue
  • Archive
  • Subject Collections

For Authors

  • Submit a Manuscript
  • Author Guidelines
  • License, copyright, Fee

Other Services

  • Alerts
  • Twitter
  • RSS Feeds

More Information

  • Editors & Staff
  • Reviewer Guidelines
  • Feedback
  • Licensing and Reuse
  • Privacy Policy

ISSN: 2575-1077
© 2023 Life Science Alliance LLC

Life Science Alliance is registered as a trademark in the U.S. Patent and Trade Mark Office and in the European Union Intellectual Property Office.